626 related articles for article (PubMed ID: 11675917)
1. [Hormone therapy of locally advanced and metastatic prostate carcinoma].
Rübben H
Praxis (Bern 1994); 2001 Sep; 90(38):1641-4. PubMed ID: 11675917
[TBL] [Abstract][Full Text] [Related]
2. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
3. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
4. [Neoadjuvant therapy of prostate carcinoma].
Ebert T
Praxis (Bern 1994); 1997 Nov; 86(46):1815-8. PubMed ID: 9454282
[TBL] [Abstract][Full Text] [Related]
5. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
[TBL] [Abstract][Full Text] [Related]
6. [Future prospects for primary hormone therapy in localized and locally advanced prostate cancer].
Akaza H; Hirao Y; Labrie F; Soloway MS
Hinyokika Kiyo; 2003 Dec; 49(12):771-7. PubMed ID: 14978964
[TBL] [Abstract][Full Text] [Related]
7. The benefits of early androgen blockade.
Maroni PD; Crawford ED
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):317-29. PubMed ID: 18471789
[TBL] [Abstract][Full Text] [Related]
8. [LHRH analogues for the treatment of prostate cancer: an evidence level-based analysis].
Pfitzenmaier J; Altwein JE
Aktuelle Urol; 2009 Mar; 40(2):100-8. PubMed ID: 19253209
[TBL] [Abstract][Full Text] [Related]
9. Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer.
Abrahamsson PA; Anderson J; Boccon-Gibod L; Schulman C; Studer UE; Wirth M
Eur Urol; 2005 Dec; 48(6):900-5. PubMed ID: 16257109
[TBL] [Abstract][Full Text] [Related]
10. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant total androgen suppression and radiotherapy in the management of locally advanced prostate cancer.
Roach M
Semin Urol Oncol; 1996 May; 14(2 Suppl 2):32-7; discussion 38. PubMed ID: 8725889
[TBL] [Abstract][Full Text] [Related]
12. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer.
Bolla M
Eur Urol; 1999; 35 Suppl 1():23-5; discussion 26. PubMed ID: 10081699
[TBL] [Abstract][Full Text] [Related]
14. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
Tsukamoto S; Akaza H
Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140
[TBL] [Abstract][Full Text] [Related]
15. Re: Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?
Rogers C
J Urol; 2003 Nov; 170(5):1955; author reply 1955-6. PubMed ID: 14575038
[No Abstract] [Full Text] [Related]
16. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer.
Siddiqui SA; Boorjian SA; Blute ML; Rangel LJ; Bergstralh EJ; Karnes RJ; Frank I
BJU Int; 2011 Feb; 107(3):383-8. PubMed ID: 21265985
[TBL] [Abstract][Full Text] [Related]
17. [Basic principles and initial results of adjuvant hormone therapy and irradiation of prostatic carcinoma].
Dearnaley DP; Shearer RJ; Ellingham L; Gadd J; Horwich A
Praxis (Bern 1994); 1997 Nov; 86(48):1895-901. PubMed ID: 9480509
[TBL] [Abstract][Full Text] [Related]
18. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
19. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
[TBL] [Abstract][Full Text] [Related]
20. New trends in prostatic cancer research. Hormone therapy in localized carcinoma of the prostate.
Perez CA
Rays; 2000; 25(3):345-51. PubMed ID: 11367900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
